Clinical trial / 2012
Daily multivitamin supplementation modestly but significantly reduced total cancer incidence in male physicians.
The Physicians' Health Study II evaluated whether a daily multivitamin compared with placebo reduces cancer risk among 14,641 male US physicians followed for a median of 11.2 years. Men taking a daily multivitamin had a statistically significant reduction in total cancer incidence (17.0 vs 18.3 events per 1000 person-years; HR, 0.92; 95% CI, 0.86-0.998; P=.04). No significant effects were observed for prostate cancer (HR, 0.98; P=.76), colorectal cancer (HR, 0.89; P=.39), other site-specific cancers, or cancer mortality (HR, 0.88; 95% CI, 0.77-1.01; P=.07). A reduction in total cancer was seen among men with a baseline history of cancer (HR, 0.73; 95% CI, 0.56-0.96; P=.02), which did not differ significantly from men without baseline cancer (P for interaction = .07).
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 14,641 male US physicians aged 50 years or older (mean age 64.3 years)
- What was measured
- Total cancer (excluding nonmelanoma skin cancer) and site-specific cancers
THE PAPER
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial.
Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, Manson JE, Glynn RJ, Buring JE. JAMA, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.